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Activation of transglutaminase type 2 for aortic
wall protection in a rat abdominal aortic aneurysm
formation
Takashi Munezane, MD, Tomomi Hasegawa, MD, PhD, Suritala, MD, Akiko Tanaka, MD,
Kenji Okada, MD, PhD, and Yutaka Okita, MD, PhD, Kobe, Japan
Objective: The altered structure and composition of the vascular extracellular matrix (ECM) influences the formation of
abdominal aortic aneurysms (AAA). Transglutaminase type 2 (TG2), which is a Ca2-dependent cross-linking enzyme,
has been proven the importance for ECMhomeostasis, but there is no evidence of TG2 in AAA formation. The hypothesis
was investigated that TG2 contributes to protect aortic walls during remodeling of the AAAs.
Methods: In a rat abdominal aortic aneurysmmodel using a combination of intraluminal elastase infusion and extraluminal
calcium chloride, TG2 expression and activity were evaluated at 1 and 8 weeks after the AAA preparation (n  6 at each
endpoint), compared with those of the non-prepared aorta (n  6). Additionally, ex vivo experiments of isolated AAA
tissue culture with recombinant human TG2, TG2 inhibitor cystamine, or tissue necrosis factor (TNF)- were
performed.
Results: TG2 mRNA expression in the AAAs was significantly upregulated at both 1 and 8 weeks (22.4-fold and 5.4-fold
increases of the non-prepared aorta, P  .0022 and P  .0048, respectively). TG2 protein expression and activity were
also enhanced by fluorescent staining of the AAAs. Similar mRNA upregulation of TNF-, interleukin-1, matrix
metalloproteinases (MMP)-2, MMP-9, and tissue inhibitors of metalloproteinases (TIMP)-1 and TIMP-2 was observed
in the AAAs, and TG2 and TNF-were colocalized in the aortic walls at 1 week. Ex vivo experiments showed that mRNA
expressions of TNF-, MMP-2, andMMP-9 in the cultured AAA tissue were decreased by exogenous TG2, whereas were
increased by cystamine. TNF- exposure to the AAA tissues was significantly upregulated TG2 mRNA expression (P 
.0333).
Conclusion: TG2 expression and activity in AAA formation were enhanced, possibly due to compensatory reaction. TG2
has a potential role of ECM protector in aortic walls during remodeling of the AAAs. (J Vasc Surg 2010;52:967-74.)
Clinical Relevance: Abdominal aortic aneurysm (AAA) is a degenerative disease characterized by impaired aortic wall
integrity, mainly due to an alteration of structure and composition of vascular extracellular matrix (ECM) through both
cellular and extracellular mechanisms. Transglutaminase type 2 (TG2), which is a Ca2-dependent cross-linking enzyme, has
been proven an importance for ECMhomeostasis, but there is no evidence inAAAs. The present study demonstrated that TG2
expression and activity were enhanced in AAA formation, possibly due to compensatory reaction. TG2 has a potential role as
ECM protector in AAA formation, and might be important for AAA prevention and treatment.Abdominal aortic aneurysms (AAAs) are degenerative
diseases characterized by impaired aortic wall integrity,
leading to dilation and eventual fatal rupture. AAA devel-
opment proceeds by a multifactorial process including en-
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ation of the structure and composition of the vascular
extracellular matrix (ECM) through both cellular and ex-
tracellular mechanisms.1 Although the ECM alteration
promoted by an imbalance between its biosynthesis and
degradation,2-6 vascular remodeling by the ECM alteration
in the AAAs remains poorly understood.
The three dimensional ECM, which consists of elastin,
collagens, laminin, heparin sulfate, proteoglycans, and
other glycoproteins, provides a structural framework and
interaction essential for the aortic walls. The ECM could be
hydrolyzed by proteases such as matrix metalloproteinases
(MMPs), and their activation and/or inhibition should be
controlled by endogenous metalloproteinase inhibitors,
termed tissue inhibitors of metalloproteinases (TIMPs).
During AAA formation, the balance between MMPs and
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the induction of their gene expression and production in
the aortic walls, resulting in a decrease and destruction
of the ECM.7,8
Transglutaminase type 2 (TG2), also called tissue trans-
glutaminase, is another regulator in the ECMorganization.
TG2 belongs to a family of Ca2-dependent enzymes that
catalyze the transfer of the -carboxamide group from
protein-bound glutamine residue to the ε-amino group of
protein-bound lysine residues or other primary amine, and
are ubiquitously expressed including in endothelial cells,
smooth muscle cells, and monocytes-macrophages.9 TG2
has many functions as a result of its ability to cross-link a
variety of intracellular and extracellular proteins, leading to
effects on cell adhesion, wound healing, tissue fibrosis,
ECM stability,10 inflammation,11 apoptosis,12 arterial cal-
cification,13,14 and angiogenesis.15 Interestingly, TG2 has
been reported as a unique gene product that contributes to
cell survival in some contexts but cell death in others.16 A
ability of TG2 as a mediator of apoptotic cell ingestion by
macrophages has previously been demonstrated,12,17 while
anti-apoptotic function of TG2 as a protective effect has
been discovered with a recent investigation.16,18,19 The
function of this multifunctional protein is considered to be
dictated by its isoform type, its cellular localization, inter-
action with other proteins, and binding to cofactors.16,20
To our knowledge, however, there are no reports in the
literature of the role of TG2 in vascular injury models. TG2
expression in AAA formation has not been investigated yet.
The purpose of the present study is to evaluate aortic
TG2 expression and activity in a rat AAA model, and to
elucidate a potential role of TG2 for AAA formation.
MATERIALS AND METHODS
Rats. Thirty-six male Sprague-Dawley rats (8 weeks of
age, CLEA Japan Inc, Tokyo, Japan) were used in the
present study. The handling of laboratory animals and their
use in experiments conformed to the Guidelines for Animal
Experiment at Kobe University Graduate School of Medi-
cine (Permission number: P080701) and the Guide for the
Care and Use of Laboratory Animals (www.nap.edu/
catalog/5140.html).
AAA preparation. Experimental AAA model was cre-
ated by means of a simple application of both intramural
elastase and extraluminal calcium chloride, according to
our recently described method.21 Briefly, rats anesthetized
with an intra-peritoneal administration of pentobarbiturate
(1 mg/kg) were placed under an operating microscope
Leica M651 (Leica Microsystems, Heerbrugg, Switzer-
land) with 6 to 10 times magnification. After a midline
abdominal incision and an abdominal aorta exposure, 30 U
of elastase (135 U/mg; Elastin Products, Owensville, Mo)
was applied to the 1 cm infrarenal aorta intraluminally and
0.5 M of CaCl2 (Sigma-Aldrich, Tokyo, Japan) extralumi-
nally for 20 minutes. The abdominal incision was closed in
layers and the rats were allowed to recover.
Aortic tissue culture. Aortic tissue culture was per-
formed as previously described13 with modification. Briefly, 1cm infrarenal aortas were harvested under sterile conditions
from rats. The harvested aortas were cut into equal halves
and placed immediately in serum-free Dulbecco’s modified
Eagle’s medium supplemented with 100U/mL penicillin/
streptomycin (Invitrogen, Carlsbad, Calif) at 37°C in a 5%
CO2 incubator for 3 days.
Study design. First, 18 rats were used for the in vivo
experiments. The 1 cm aortic segments in the rat AAA
model at 1 and 8 weeks after the AAA-preparation (n  6
rats, respectively) were harvested and evaluated as com-
pared with age-matched unprepared rats (no AAA prepara-
tion; n  6 rats). Next, 18 rats were used for the ex vivo
experiments. At 1 week after AAA preparation, the 1 cm
AAA tissues were harvested and cut into equal halves. In
first ex vivo experiment (six rats), one of the two AAA
segments were cultured with recombinant human TG2
(5g/mL; R&D Systems, Minneapolis, Minn), and an-
other AAA segments were cultured with TG2 inhibitor
cystamine (20 g/mL; Sigma-Algrich) as mentioned
above (n  6 segments, respectively). In second ex vivo
experiment (six rats), one of the two AAA segments were
cultured with tissue necrosis factor (TNF)- (100U/mL:
Sigma-Algrich), and another were cultured without TNF-
(n 6 segments, respectively). As a control group (six rats),
one of the two AAA segments were cultured without
recombinant human TG2 or cystamine for the first ex vivo
experiment; another was not cultured for the second ex
vivo experiment (n  6 segments, respectively).
Macroscopic assessments. Animals were anesthetized,
and then the abdominal aorta was exposed. The aneurysmal
diameter, defined as the maximal dimension of the trans-
verse minor axis of the abdominal aorta, and the aortic
diameter at the infrarenal proximal neck site, was measured
under physiologic conditions with an optical micrometer
before harvest. The dilation ratio was calculated according
to the following formula: Dilation ratio (%) ([aneurysmal
diameter – aortic diameter]/aortic diameter)  100. The
AAA is defined as when the dilation ratio is more than
50%.21
Quantitative real-time polymerase chain reaction
(PCR) analysis. Total RNA was isolated from AAA sam-
ples using an RNeasy fibrous tissue mini-kit (Qiagen K.K.,
Tokyo, Japan) according to manufacturer’s instructions. The
RNA was transcribed and amplified to cDNA using a High
capacity cDNA reverse transcription kit (Applied Biosystems,
Foster City, Calif). Quantitative real-time (PCR) analysis for
mRNA of TG2, MMP-2, MMP-9, TIMP-1, TIMP-2,
Table. Macroscopic measurement of abdominal aortic
aneurysm
1 week 8 weeks
Aortic diameter, mm 2.0  0.1 1.9  0.3
Aneurysmal diameter, mm 3.1  0.1 3.5  0.4
Dilation ratio, % 51.8  3.5 86.0  8.8TNF-, and interleukin (IL)-1 was performed using ABI
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with TaqMan universal PCR master mix and TaqMan real-
time PCR primers (Applied Biosystems). The mRNA
primer of TG2 was for a full-length TG2 isoform. The
expression level of each mRNA was divided by mRNA level
of the housekeeping gene glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH).
Immunofluorescent staining. Immunofluorescent stain-
ing was performed on frozen sections with primary anti-
body, rabbit polyclonal anti-human TG2 antibody, and
mouse anti-rat TNF- (catalog number, sc-20621 and
sc-1350, respectively; Santa Cruz Biotechnology, Santa
Cruz, Calif). This TG2 antibody (amino acid 451-686) was
against both full-length TG2 isoform (amino acid 1-686)
and short chain TG2 isoform (amino acid 1-548). For
detection of these antibodies, fluorescein-linked donkey
anti-rabbit antibody and Texas Red-linked sheep anti-
mouse antibody (Amersham Biosciences, Buckingham-
shire, UK) were respectively used as secondary antibodies.
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Fig 1. TG2 expression in AAAs. (A) Relative TG2 mRN
expression and enzyme activity. Bar 100m.AAA,Ab
prep, non-prepared aorta; TG2, transglutaminase type 2.
for six rats per group.Cell nuclei were counterstained with 4=,6-diamidino-2-phenylindole (DAPI; Pierce, Rockford, Ill). Images were cap-
tured under a BZ-8100microscopic system (KEYENCECo.,
Osaka, Japan).
TG2 activity. TG2 activity was evaluated on frozen
sections as previously described with somemodifications.22
Briefly, for detection of TG2 enzyme activity, AAA sections
were preincubated with TG2 assay buffer (965 L of 100
mM Tris/HCl [pH 7.4], 25 L of 200 mM CaCl2) for 15
minutes and then with the same TG2 assay buffer added
Tex-Red cadaverine (Molecular Probes/Invitrogen, Eu-
gene, Ore) for 1 hour at 37°C. The reaction was stopped
with 25 mM EDTA for 5 minutes. The cell nuclei were
counterstained with DAPI (Pierce) before mounting with
antifade mounting medium (Vector Laboratories, Burlin-
game, Calif). Fluorescence was visualized by using a BZ-
8100 microscopic system (Keyence Co).
Statistics. Database management and statistical analy-
sis were performed with Statview version 5.0 software (SAS
Institute Inc, Cary, NC). All values are expressed as means
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Student t-test. Values of P 	 0.05 were considered statis-
tically significant.
RESULTS
Aneurysm formation. There was neither technical
failure nor death intraoperatively, and all animals have
survived until each endpoint uneventfully. The aneurysm
Fig 2. Messenger RNA expression of proinflammatory
IL-1, MMP-2, andMMP-9. (B)TIMP-1 and TIMP-2.
aorta;GAPDH, glyceraldehyde-3-phosphate dehydrogen
non-prepared aorta; NS, not significant; TIMP, tissue in
data are expressed as mean  standard error of the meanformation was observed in three of six animals (50%) at 1week, in all of six animals (100%) at 8 weeks. The AAA
dilation ratios at 1 and 8 weeks were 51.8%  3.5% and
86.0%  8.8% respectively (Table).
TG2 expression and activity in AAAs. Relative TG2
mRNA expression in the AAAwas significantly upregulated
with 22.4 5.2 times of the non-prepared aorta at 1 week
(P  .0022), and 5.4  1.2 times at 8 weeks (P  .0048;
Fig 1A). Fluorescent staining has shown that both TG2
ines and MMPs in AAAs at 1 and 8 weeks. (A) TNF-,
,Abdominal aortic aneurysm;AAA prep,AAA-prepared
L, interleukin;MMP,matrix metalloproteinase;No prep,
rs of metalloproteinase; TNF, tissue necrosis factor. All
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compared with those of the non-prepared aorta (Fig 1B). At
1 week, there were no significant differences of those TG2
expression and activity levels in comparison between the an-
eurismal and nonaneurysmal aortas (data not shown).
Inflammatory response in AAAs. Inflammation plays a
pivotal role in AAA formation by direct production of proin-
flammatory cytokines such as TNF- and IL-1, and MMPs
such as MMP-2 and MMP-9.2 Compared with the non-
prepared aorta, all of these mRNA expressions in the AAAs
were significantly upregulated at 1 week, and then decreased
but kept their significant upregulation at 8 weeks (Fig 2A).
Both TIMP-1 and TIMP-2 mRMA expressions were also
significantly upregulated at 1 week, and kept their upregula-
tion without statistical significances at 8 weeks (Fig 2B).
Colocalization of TG2 and TNF-. To investigate
the colocalization of TG2 and TNF- protein in AAAs,
double immunofluorescent staining for TG2 and TNF-
was performed. The immunoreactivity of both TG2 and
TNF- was diffusely enhanced throughout the aortic
wall as compared with the non-prepared aorta (Fig 3).
Ex vivo experiments. To further clarify the effect of
TG2 on AAA formation, isolated AAA tissues were incu-
bated with recombinant human TG2, TG2 inhibitor cysta-
mine, or TNF-. After 3-day incubation with exogenous
TG2,mRNA expressions of TNF-, MMP-2, andMMP-9 in
the AAA tissues were decreased, with 0.63  0.16, 0.55 
0.06, and 0.12 0.03 times of those after 3-day incubation
with the control, respectively. On the other hand, after
3-day incubation with cystamine, mRNA expressions of
TNF-, MMP-2, and MMP-9 in the AAA tissues were
increased, with 1.27 0.28, 1.43 0.39, and 1.69 0.65
times of those after 3-day incubation with the control,
respectively. There were significant differences of MMP-2
and MMP-9 mRNA expression in the aortic tissues, com-
pared between exogenous TG2 and cystamine treatment
(Fig 4). Three-day incubation with TNF- induced a sig-
nificant upregulation of TG2 mRNA in the AAA tissues as
AAA prep.
No prep.
TG2 TNF
Fig 3. Double immunofluorescent staining for TG2 (g
TNF- are indicated as a yellow emission. Cell nuclei a
Abdominal aortic aneurym; AAA prep, AAA-prepared
prepared aorta; TG2, transglutaminase type 2; TNF, tisscompared with 3-day incubation without TNF- (4.0 1.4 vs 0.47  0.08 times of the preculture, P  .0333;
Fig 5).
DISCUSSION
Vascular remodeling, which is any enduring change in
the size, structure or composition of vessels, underlies the
pathogenesis of major cardiovascular diseases. It induces
degradation and reorganization of the ECM in the vascular
wall, and tunes the vasculature to the surrounded environ-
ment. Aortic aneurysms develop as a result of a complex
series of vascular remodeling that dynamically alter the
aortic ECM, and the process is associated with the conse-
quence of dysregulated balance between matrix biosynthe-
sis and degradation.23 Recently, it has become clear that
TG2 forms ECM cross-links and plays a crucial role in the
vascular remodeling.24 Although many new evidences of
TG2 have been proven,25-27 a potential role of TG2 for the
vascular remodeling process during aneurysm formation is
still unknown.
To our knowledge, the present study is the first to
investigate the effects of TG2 on AAA formation. The
notable finding of the present study is that TG2 expression
and activity were increased during AAA formation, espe-
cially in the acute phase. Inflammation is believed to play an
etiological role in AAA formation by direct local produc-
tion of proinflammatory cytokines such as TNF- and
IL-1, and subsequent elaboration of MMPs such as
MMP-2 and MMP-9.2,21 Our recent report has demon-
strated that CD3- and CD11b-positive inflammatory cells
were infiltrated into the aortic wall in rat AAA model.21 In
the present study, mRNA expression of TNF-, IL-1,
MMP-2, and MMP-9 was upregulated with similar prop-
erties to that of TG2. There was also the enhanced colocal-
ization of TG2 and TNF- protein in the whole wall of
AAAs by the double immunofluorescent staining. Previ-
ously, Sumi et al demonstrated that TNF- plays an impor-
tant role in the TG2 upregulation in human atherosclerotic
coronary arteries.17 Particularly intriguing questions that
DAPI Merge
) and TNF- (red). Sites of colocalization of TG2 and
unterstained with DAPI (blue). Bar  100 m. AAA,
DAPI, 4=,6-diamidino-2-phenylindole; No prep, non-
crosis factor.-α
reen
re co
aorta;remain to be addressed are whether the TG2 upregulation
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whether it works beneficially or harmfully to the aortic wall.
Both TIMP-1 and TIMP-2 mRNA expressions were
also upregulated with similar properties to that of TG2 in
this study. It is well known that TIMPs, which are ubiqui-
tously produced in the aortic ECMmilieu, reduce excessive
proteolytic ECM degradation by an inhibition of the
MMPs.28 Previous studies have demonstrated that TIMP-1
Fig 4. Messenger RNA expression of TNF-, MMP-2, and
MMP-9 after 3-day incubation of isolated AAA segments with
exogenous transglutaminase type 2 (TG2) or TG2 inhibitor cysta-
mine (Cys), or without them (Conrol). The AAA segments were
harvested at 1 week after AAA preparation in the rat AAA model.
Cys,Cysteine; IL, interleukin;MMP,matrixmetalloproteinase;NS,
not significant; TG2, transglutaminase type 2; TNF, tissue necrosis
factor. All data are expressed as mean standard error of the mean
for six independent analyses.and TIMP-2 were increased in AAAs as well as MMPs.29-31This suggests that TIMPs can be activated as a compensa-
tory or protective reaction in response to the MMPs acti-
vation during AAA formation. Currently, Ahn et al32 have
reported that TG2 downregulates MMP-9 mRNA, pro-
tein, and activity levels in vitro experiments. Ientile et al11
suggested that various stimuli or insults are able to induce
TG2 activation following cell stress and injury. Based on
these evidences of TIMPs and TG2, we hypothesized that
TG2 expression could be indirectly activated for aortic wall
protection following to the ECM degradation in the aneu-
rysm formation.
To elucidate the causal relationship between TG2 and
AAA formation, we have designed ex vivo experiments of
isolated AAA tissue culture. The experiments showed that
mRNA expressions of TNF-, MMP-2, andMMP-9 in the
cultured AAA tissues were suppressed by exogenous TG2,
whereas enhanced by TG2 inhibitor cystamine. There were
no statistically significant differences in IL-1, TIMP-1,
and TIMP-2 (data not shown). Because TNF-, MMP-2,
and MMP-9 have potential biomarkers for AAA develop-
ment,2,33 these results indicate TG2 play can play a protec-
tive role for the aortic tissues in the anerysm formation.
Furthermore, the experiments showed that TNF- stimu-
lation caused an increase of TG2 mRNA expression in the
cultured AAA tissues. This result suggests that enhance-
ment of the aortic TG2 expression and activity could be
part of the compensatory response evoked by inflammatory
reactions during aneurysm formation. The interest in TG2
has been increasing because of its multifunctional activity in
most tissues capable of enzymatic, cell adhesion, and cell
signaling.20 Recent reports have shown that TG2-mediated
cross-linking of intracellular proteins can protect against
apoptosis.16,18,19 Therefore, it is not surprising that the
increased expression and activity of TG2 are associated with
its compensatory protective response in the acute phase of
AAA formation. Nicholas et al have described interestingly
Fig 5. Messenger RNA expression of TG2 after 3-day incubation
of isolated AAA segments with/without TNF-. The AAA seg-
ments were harvested at 1 week after AAA preparation in the rat
AAA model. The data were compared with TG2 mRNA level
before tissue culture. TG2, Transglutaminase type 2; TNF, tissue
necrosis factor; pre, preculture. All data are expressed as mean 
standard error of the mean for six independent analyses.that TG2 upregulation following tissue insult could con-
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TG2 could be related to apoptosis or cell death.34 Ant-
onyak et al have reported that full-length TG2 can protect
against cellular insults, while the short chain TG2 seems to
promote cell death. These might be clues for AAA forma-
tion and development.
In the present study, the level of TG2 upregulation in
AAA formation had a tendency to relate to the AAA size at
1 week, although the correlation was not significant,
whereas not at 8 weeks (data not shown). However, it was
interesting that formation TG2 activity level was very low in
the chronic phase of AAA. Reduced TG2 activity has re-
cently been implicated in cardiac dilation and dysfunction
after myocardial infarction,35 and it is believed that imbal-
ance of ECM metabolism is responsible for the excessive
elastic degradation leading to AAA formation.36 The inac-
tivation of TG2 activity or the imbalance of TG2 expression
in the aortic ECM milieu might contribute to AAA forma-
tion. Further studies are needed to evaluate the correlation
between TG2 expression/activity and AAA development.
TG2 is a calcium-dependent cross-linking enzyme.9
Because our AAA model was based on elastolysis and Ca2
incubation, we have performed preliminary examination
using an AAA preparation with only elastolysis or only
Ca2 incubation. As described in our previous article,21
aneurysm formation was hardly observed at 4 weeks by
those preparations. TG2 mRNA expression in aorta with
elastolysis- or Ca2-preparation was not significantly differ-
ent from that in non-prepared aorta. This result suggests
that AAA formation activated TG2 expression independent
of elastolysis or Ca2 incubation. Arterial calcification13,14
and angioneogenesis15 were recently reported as one of
TG2 multifunctional roles in vascular cells. In the present
study, microscopic findings did not shown apparent calci-
fication or angiogenesis in AAAs at 8 weeks after prepara-
tion. It might be because there was little increase of TG2
expression in AAA at 8 weeks. Further studies are needed to
clarify the TG2 effects on arterial calcification and angio-
genesis in AAA formation.
In the clinical settings, there are currently no therapeu-
tic approaches to prevent AAA, leaving patients with surgi-
cal or endovascular therapy as their only option. As far as
the contribution of extracellular TG2 as a matrix stabilizer
is concerned, much attention has recently focused on the
potential importance of TG2 as a therapeutic target. In
addition, its medical applications of TG2 in the generation
of naturally cross-linked biomaterials have been widely
investigated.37 We believe that TG2 might provide the
crucial link between functional and structural modulation
of the aortic vascular wall to prevent or treat AAA diseases.
This study presents some limitations that deserve atten-
tion. The first limitation is that the present rat AAA model
lacks several prominent features of the human lesion such as
atherosclerosis and intraluminal thrombosis. However, we
demonstrated that this AAA model is simple and easy to
perform and is highly reliable and reproducible to create a
saccular aneurysm.21 The second limitation is that there are
not any data regarding whether the same upregulation isseen in other aneurysm models right now. The third limi-
tation is represented by the lack of TG2 analyses for cell
localization or signal transduction mechanism analysis. We
did not determine whether transduction and deamidation
of ECM proteins by TG2 modulates matrix-cell communi-
cation in AAA formation. Further studies are needed to
elucidate an essential role of TG2 in the mechanistic path-
way of AAA formation, and then these results will have to
be confirmed with human AAA microarray and protein
analysis.
In conclusion, the present study demonstrated a poten-
tial role of TG2 as an ECM protector in the vascular
remodeling process of AAA formation. Its expression and
activity was enhanced especially in the acute phase of the
AAA formation, possibly due to compensatory reaction.
Theremight be the importance and therapeutic potential of
TG2 in AAA development.
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